Literature DB >> 22475362

Bleeding-avoidance strategies and outcomes in patients ≥80 years of age with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the NCDR CathPCI Registry).

John A Dodson1, Yongfei Wang, Sarwat I Chaudhry, Jeptha P Curtis.   

Abstract

The purpose of our study was to evaluate the use of bleeding-avoidance strategies (BAS) and risk-adjusted bleeding over time in patients ≥80 years of age undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction. We analyzed data from the CathPCI Registry from July 1, 2006 through June 30, 2009. Patients were included if they were ≥80 years old, presented with ST-segment elevation myocardial infarction, and underwent primary PCI. We evaluated trends in use of BAS (direct thrombin inhibitors, vascular closure devices, and radial access) and risk-adjusted bleeding over time. Of 10,469 patients ≥80 years old undergoing primary PCI, 1,002, (9.6%) developed a bleeding complication. Use of direct thrombin inhibitors and vascular closure devices increased over time (12.8% to 24.9% and 29.2% to 32.7%, p <0.01 and <0.05 for trends, respectively). Radial access was extremely uncommon (<1%) and did not change over the course of the study. In multivariable analyses, use of BAS was associated with lower bleeding. However, over the course of the study period, overall risk-adjusted bleeding did not decrease significantly (9.9% to 9.4%, p = 0.14 for trend). In conclusion, patients ≥80 years old undergoing primary PCI are at high risk of bleeding, and despite significant increases in use of BAS, the overall rate of bleeding complications remains high.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22475362      PMCID: PMC3666171          DOI: 10.1016/j.amjcard.2012.02.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository.

Authors:  R G Brindis; S Fitzgerald; H V Anderson; R E Shaw; W S Weintraub; J F Williams
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

2.  A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention.

Authors:  Paul T Vaitkus
Journal:  J Invasive Cardiol       Date:  2004-05       Impact factor: 2.022

3.  A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices.

Authors:  Nipun Arora; Michael E Matheny; Carrie Sepke; Frederic S Resnic
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

Review 4.  Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI.

Authors:  Ronald P Caputo; Jennifer A Tremmel; Sunil Rao; Ian C Gilchrist; Christopher Pyne; Samir Pancholy; Douglas Frasier; Rajiv Gulati; Kimberly Skelding; Olivier Bertrand; Tejas Patel
Journal:  Catheter Cardiovasc Interv       Date:  2011-05-04       Impact factor: 2.692

5.  Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).

Authors:  Alvaro Avezum; Marcia Makdisse; Frederick Spencer; Joel M Gore; Keith A A Fox; Gilles Montalescot; Kim A Eagle; Kami White; Rajendra H Mehta; Elias Knobel; Jean-Philippe Collet
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

6.  Risk-treatment mismatch in the pharmacotherapy of heart failure.

Authors:  Douglas S Lee; Jack V Tu; David N Juurlink; David A Alter; Dennis T Ko; Peter C Austin; Alice Chong; Therese A Stukel; Daniel Levy; Andreas Laupacis
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

7.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.

Authors:  Karen P Alexander; Anita Y Chen; Matthew T Roe; L Kristin Newby; C Michael Gibson; Nancy M Allen-LaPointe; Charles Pollack; W Brian Gibler; E Magnus Ohman; Eric D Peterson
Journal:  JAMA       Date:  2005-12-28       Impact factor: 56.272

8.  Bivalirudin for patients with acute coronary syndromes.

Authors:  Gregg W Stone; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; Stuart J Pocock; James H Ware; Frederick Feit; Antonio Colombo; Philip E Aylward; Angel R Cequier; Harald Darius; Walter Desmet; Ramin Ebrahimi; Martial Hamon; Lars H Rasmussen; Hans-Jürgen Rupprecht; James Hoekstra; Roxana Mehran; E Magnus Ohman
Journal:  N Engl J Med       Date:  2006-11-23       Impact factor: 91.245

9.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).

Authors:  M Moscucci; K A A Fox; Christopher P Cannon; W Klein; José López-Sendón; G Montalescot; K White; R J Goldberg
Journal:  Eur Heart J       Date:  2003-10       Impact factor: 29.983

Review 10.  Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis.

Authors:  Maria Koreny; Eva Riedmüller; Mariam Nikfardjam; Peter Siostrzonek; Marcus Müllner
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

View more
  2 in total

1.  Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly.

Authors:  Bimmer E P M Claessen; Wouter J Kikkert; Loes P Hoebers; Hassina Bahadurzada; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan G P Tijssen; Jan J Piek; José P S Henriques
Journal:  Neth Heart J       Date:  2015-09       Impact factor: 2.380

Review 2.  Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction.

Authors:  Lei Gao; Xin Hu; Yu-Qi Liu; Qiao Xue; Quan-Zhou Feng
Journal:  Clin Interv Aging       Date:  2014-07-31       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.